Acomplia (Rimonabant) was approved for sale in the UK on June which means the introduction of this drug is new. Acomplia has not yet got FDA (Food and Drug Administration) approval for sale in the US. Sanofi-Aventis is the manufacturer of Acomplia, which is a French pharmaceutical firm. The drug is prescribed for suppressing appetite in an obese person. The suppression of appetite helps in lowering calorie intake thereby reducing obesity. During its trial period the manufacturer also claimed of this drug having smoking cessation effect.
As the introduction of this drug is new the success of this drug remains to be seen. But the real problem is the availability of the drug. At present only a few numbers of pharmacies are keeping it with them as FDA has not approved its use as a weight loss pill. Till the moment when FDA approves the drug, the pharmacies in US would be having tough time assuring the customers of its arrival soon.
The clinical results of Acomplia (Rimonabant) for 2 years showed much promise for this new weight loss drug. In the clinical trials around 40% of the sample lost 10% or more weight as a result of taking the drug. Apart from that the cardiovascular and metabolic risk factors related to obesity are minimised. These all are leading to a wide spread notion that Acomplia would help an obese person get slimmer when taken. The initial results of the effects of Acomplia from EU and UK is satisfactory to Sanofi-Aventis standards. But the success stories which are remaining to be unfolded from UK and EU where it has been launched last month, would only state whether this diet pill Acomplia would stand the test of time.
Howsoever successful the effects of Acomplia may be as a weight loss pill there certainly would be some side effects like nausea, dizziness, insomnia and stomach upset etc. which a user might have to deal with. But the side effects have much lower intensity than other similar diet pills. The pill must be taken with consultation of a doctor to get its maximum effect on weight loss. A person with heart disease, blood pressure, diabetes, allergy and hypertension should tell a doctor first before going for the drug. Children, pregnant woman and breast feeding mothers too should consult doctor if they are to take the pill.
Uk And The Eu
The objective of the Waste Electrical and Electronic Equipment (WEEE) Directive 2002/96/EC is to minimize the environmental impact of electronic waste. The WEEE directive protects landfills and regulates the disposal of discarded or end-of-life electrical or electronic equipment (EEE) also known as e-waste. The related RoHS Directive 2002/95/EC strives to limit the use of six hazardous materials in the manufacture of electronic equipment.
The WEEE Directive provides guidelines for the collection, treatment, recycling and recovery of waste electrical and electronic equipment. The "polluter pays" principle means collection and recovery is largely at the manufacturer's expense. Specified products include such things as large and small household appliances, IT and telecommunications equipment, consumer equipment, IT and telecommunications equipment.
Reduction of hazardous material content in products at the manufacturing stage will reduce the content of such pollutants in electronic waste. This will enhance the economic feasibility of recycling. Hence RoHS compliance, which in any case is needed for doing business in the EU, is the first important element for any effective recycling. Increased efforts to design products that facilitate recycling of WEEE components and materials are extremely beneficial.
Recycling is one of several waste disposal options. Its effectiveness depends, to a large extent on the type of material to be recycled and the availability of appropriate technology. E-waste such as a computer can be discarded by the original users, but it may still be perfectly functional equipment. In this case material recovery and reuse is a better alternative than recycling. In fact the reuse of waste electrical and electronic equipment is the preferred economic option.
Recycling is technology and material specific. It is mandatory to collect electronic waste separately from municipal waste. While primary administrative responsibility lies with the state, manufacturers have an important role in educating customers on proper waste disposal. The WEEE directive mandates collection of electronic waste at the manufacturer's cost. Manufacturers must not only ensure that convenient collection points are set up for consumers but must also make provisions for the transportation of the waste materials to the recycling plant.
The WEEE directive mandates that recycling sites should conform to certain minimum standards to prevent adverse environmental impact when treating waste EEE. In most cases, it will not be feasible for a single manufacturer to operate its own recycling center.
Throughout the WEEE recovery chain, producers are required to finance the cost of e-waste collection from consumers; transportation to the recycling center; treatment; recovery and disposal. Producers will generally need to collaborate with other manufacturers to collectively bear the cost for the recycling and waste disposal obligations.
The WEEE and the RoHS are here to stay and further strengthening of environmental regulations is inevitable. One such step is the impending Registration, Evaluation and Authorization of Chemicals (REACH), regulations effective from June 1, 2007 in the European Union. The REACH regulation will control the use of a very wide range of chemicals and is not limited only to the electronics sector. In this increasingly difficult milieu, a proactive approach by producers to comply with the WEEE electronic recycling directive will surely give them dividends for increased competitiveness.
Both Clarence Carter & Sandra Noble are contributors for EditorialToday. The above articles have been edited for relevancy and timeliness. All write-ups, reviews, tips and guides published by EditorialToday.com and its partners or affiliates are for informational purposes only. They should not be used for any legal or any other type of advice. We do not endorse any author, contributor, writer or article posted by our team.
Clarence Carter has sinced written about articles on various topics from Lose Weight, Diabetes Treatment and Lose Weight. Clarence Carter received training as a healthcare scientist. She has been working in the same field and writes informative articles, weight loss being her pet subject. To find Acomplia, Weight loss drug, weight loss pills, Acomplia (Rimonabant), Cheap Die. Clarence Carter's top article generates over 135000 views. Bookmark Clarence Carter to your Favourites.